Home / News / World News / Article /
COVID-19: Pfizer has 90 per cent effective vaccine. What happens next?
Updated On: 10 November, 2020 09:46 AM IST | New York | IANS
The Phase 3 clinical trial began on July 27. Nearly 39,000 people have received a second dose of the vaccine candidate by November 8, 2020.

Photo for representational purpose
Stock markets are booming, scientists are hailing Pfizer's vaccine which has shown 90 percent effectiveness and corporates are already imagining the sunny prospect of a return to on-campus work but Pfizer is reminding everyone that it still needs to check off three boxes before its silver bullet progresses toward emergency use authorisation.
Pfizer explains that there needs to be "success" in the following three areas: Evidence of efficacy in most vaccinated patients, evidence of safety with data from thousands of patients and manufacturing which is consistently at the highest quality standards.
How do you like the new new mid-day.com experience? Share your feedback and help us improve.

